SEC Form 4 · accession 0000899243-18-005332
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E. Hughes
Officer — See Remarks · Director
Period of report
Feb 22, 2018
Accepted (ET)
Feb 23, 2018 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.77 | Feb 22, 2018 | A | 275,000 | A | — | Feb 22, 2028 | Common Stock | 275,000 | 275,000 | D |
Explanation of responses
- F125% of this option vests on February 22, 2019, and the remainder vests in equal monthly installments thereafter over 36 months
Remarks
President and Chief Scientific Officer